To see if buprenorphine patch will result in better pain control in acute pancreatitis patients compared to intravenous tramadol
Phase 3
- Conditions
- Health Condition 1: K85- Acute pancreatitis
- Registration Number
- CTRI/2024/08/072154
- Lead Sponsor
- Dr Satinder Pal Singla
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patient with acute pancreatitis according to
revised Atlanta classification.
2.Age = 18 years.
3.Pain on VAS =7 on arrival.
Exclusion Criteria
1.Altered sensorium
2.Patient in shock/on mechanical ventilation
3.Contraindications to administration of opioids
4.Patients on chronic pain medications (taken opioids for more than or equal to 3 months with last intake in last 7 days)
•Pregnant/lactating mothers
•Chronic pancreatitis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the number of acute pancreatitis patients achieving adequate pain relief with transdermal buprenorphine patch to intravenous tramadol. Pain relief in the form of reduction of visual analogue scale score by more than or equal to 3 points or absolute reduction to less than 3 points at 36 hours from enrollment in the trial.Timepoint: 36 hours from enrollment in the trial
- Secondary Outcome Measures
Name Time Method 1.To compare the frequency of rescue analgesia required for adequate pain relief in patients of acute pancreatitis being treated with transdermal buprenorphine patch to intravenous tramadol. <br/ ><br>2.To monitor the adverse effects due to opioids treatment in patients of acute pancreatitis being treated for pain. <br/ ><br> <br/ ><br>Timepoint: At 24 hours, 36 hours, 48 hours, 72 hours